Patents by Inventor Ilhem KHELIFI

Ilhem KHELIFI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES
    Publication number: 20230203005
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Application
    Filed: March 6, 2023
    Publication date: June 29, 2023
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
  • Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties
    Patent number: 11634405
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 25, 2023
    Assignees: UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad Alami, Olivier Provot, Abdallah Hamze, Ilhem Khelifi, Timothée Naret, Sébastien Apcher, Romain Darrigrand
  • DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES
    Publication number: 20220023435
    Abstract: Disclosed are compounds having the formula (I): wherein R1 represents a group: —NH2, —NHCORa, —NHCOORb, —(C2-C6)alkenylene-CO—NH—OH, —(C2-C6)alkynylene-CO—NH—OH or —OH; R2 represents a group: —OCH3, —OCH2CH3, —SCH3, —SCH2CH3 or —OCHF2; R3 represents a hydrogen atom or a group: —CH3, —CN, —F, —Cl or —ORc; R4 represents a hydrogen atom or a group: —CH3, —CN, —F, —Cl or —ORd; Ra represents a group: —(C1-C5)alkyl or —CF3; Rb represents a group: —(C1-C5)alkyl or —CF3; Rc represents a group: —(C1-C5)alkyl or —CF3; and Rd represents a group: —(C1-C5)alkyl or —CF3; in the state of a base or acid or acid salts or base salts or in the form of hydrate or of solvate. Also disclosed are drug conjugates including such compounds.
    Type: Application
    Filed: September 17, 2019
    Publication date: January 27, 2022
    Inventors: Mouad ALAMI, Abdallah HAMZE, Olivier PROVOT, Ilhem KHELIFI, Vincent BLANCHARD, Nada MAKKY-IBRAHIM
  • COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES
    Publication number: 20210230140
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Application
    Filed: April 26, 2019
    Publication date: July 29, 2021
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND